D.E. Shaw & Co Portfolio holdings
D. E. Shaw & Co., L.P., founded in 1988 by David E. Shaw, a former Columbia University computer science professor, is a New York City-based global investment management firm renowned for pioneering quantitative investing, managing over $70 billion in assets as of late 2024. Starting with $28 million from Paloma Partners and private investors, the firm employs sophisticated mathematical models and proprietary algorithms—initially developed by a team of scientists and programmers—to exploit market anomalies across public and private markets, including equities, fixed income, and alternatives. Headquartered above a Greenwich Village bookstore in its early days, it now boasts over 2,500 employees across offices in North America, Europe, and Asia, led by a seven-member Executive Committee since Shaw stepped back in 2001 to focus on D. E. Shaw Research. Despite setbacks like the 1998 Russia debt crisis and the 2008 financial downturn, the firm has maintained a reputation for analytical rigor, risk management, and innovation, balancing its computational roots with discretionary strategies.
Top Buys
| 1 |
Apple
AAPL
|
+$773M |
| 2 |
Visa
V
|
+$674M |
| 3 |
HES
Hess
HES
|
+$541M |
| 4 |
Mastercard
MA
|
+$448M |
| 5 |
Oracle
ORCL
|
+$419M |
Top Sells
| 1 |
NVIDIA
NVDA
|
+$1.29B |
| 2 |
Advanced Micro Devices
AMD
|
+$979M |
| 3 |
Citigroup
C
|
+$477M |
| 4 |
Exxon Mobil
XOM
|
+$434M |
| 5 |
Booking.com
BKNG
|
+$355M |
Sector Composition
| 1 | Technology | 27.95% |
| 2 | Consumer Discretionary | 14.18% |
| 3 | Financials | 9.99% |
| 4 | Healthcare | 9.55% |
| 5 | Communication Services | 6.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1701
Immunovant
IMVT
$2.82B
| $1.81M | ﹤0.01% |
55,914
-52
| -0.1% | -$1.68K |
|
1702
Generation Bio
GBIO
$39.9M
| $1.81M | ﹤0.01% |
44,371
+16,060
| +57% | +$654K |
|
1703
ePlus
PLUS
$1.97B
| $1.8M | ﹤0.01% |
22,956
-35,332
| -61% | -$2.77M |
|
1704
CEVA Inc
CEVA
$564M
| $1.8M | ﹤0.01% |
79,222
-2,363
| -3% | -$53.7K |
|
1705
Design Therapeutics
DSGN
$343M
| $1.8M | ﹤0.01% |
446,190
+155,562
| +54% | +$627K |
|
1706
Organogenesis Holdings
ORGO
$625M
| $1.8M | ﹤0.01% |
632,744
-334,128
| -35% | -$949K |
|
1707
Lands' End
LE
$475M
| $1.8M | ﹤0.01% |
164,854
-14,341
| -8% | -$156K |
|
1708
PetMed Express
PETS
$57.8M
| $1.79M | ﹤0.01% |
374,021
+234,362
| +168% | +$1.12M |
|
1709
Aldeyra Therapeutics
ALDX
$324M
| $1.79M | ﹤0.01% |
547,640
+287,584
| +111% | +$940K |
|
1710
Fossil Group
FOSL
$168M
| $1.79M | ﹤0.01% |
1,754,669
-69,744
| -4% | -$71.1K |
|
1711
MGM Resorts International
MGM
$9.4B
| $1.79M | ﹤0.01% |
37,818
+21,865
| +137% | +$1.03M |
|
1712
Four Leaf Acquisition Corp
FORL
| $1.78M | ﹤0.01% |
165,000
| – | – |
|
1713
Revolve Group
RVLV
$1.59B
| $1.77M | ﹤0.01% |
83,770
-53,596
| -39% | -$1.13M |
|
1714
Wave Life Sciences
WVE
$1.11B
| $1.76M | ﹤0.01% |
+285,092
| New | +$1.76M |
|
1715
Arcellx
ACLX
$4.23B
| $1.76M | ﹤0.01% |
25,286
-41,788
| -62% | -$2.91M |
|
1716
BJ's Restaurants
BJRI
$684M
| $1.73M | ﹤0.01% |
47,832
+16,930
| +55% | +$613K |
|
1717
Adtran
ADTN
$809M
| $1.73M | ﹤0.01% |
318,038
+125,727
| +65% | +$684K |
|
1718
Dropbox
DBX
$8.34B
| $1.73M | ﹤0.01% |
71,186
+55,328
| +349% | +$1.34M |
|
1719
Mercury Insurance
MCY
$4.4B
| $1.73M | ﹤0.01% |
33,456
-49,476
| -60% | -$2.55M |
|
|
VRN
1720
DELISTED
Veren
VRN
| $1.72M | ﹤0.01% |
210,291
-578,600
| -73% | -$4.73M |
|
1721
MindMed
MNMD
$718M
| $1.72M | ﹤0.01% |
+183,029
| New | +$1.72M |
|
1722
Occidental Petroleum Corporation Warrants to Purchase Common Stock
OXY.WS
$22.5B
| $1.72M | ﹤0.01% |
39,904
| – | – |
|
1723
Trinseo
TSE
$87.7M
| $1.71M | ﹤0.01% |
453,389
+77,452
| +21% | +$293K |
|
1724
Manulife Financial
MFC
$54.2B
| $1.71M | ﹤0.01% |
68,400
-86,740
| -56% | -$2.17M |
|
1725
Pan American Silver
PAAS
$15.5B
| $1.7M | ﹤0.01% |
112,730
+10,043
| +10% | +$151K |
|